Small-Cap Momentum Watch: Upcoming Catalysts for April 27– May 1

From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.

--

Companies with Material Events This Week

● RVPH > CEO Laxminarayan Bhat will participate in an A.G.P. fireside chat on April 27, 2026 at 11:00 a.m. ET, highlighting recent developments for brilaroxazine and upcoming clinical, regulatory, and IP milestones

● OCGN > CEO Dr. Shankar Musunuri will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27–29, 2026 in Puerto Rico, while Abhi Gupta will present at the 2026 Cell & Gene Meeting on the Mediterranean from April 28–30, 2026 in Rome

● EXFY > partnered with the Institute of Commercial Payments for the 2026–2027 cycle and will participate in the IOCP Annual Commercial Card and Payment Conference from April 27–29, 2026 in Scottsdale, Arizona

● ENVB > CEO Joseph Tucker will participate in Needham’s Virtual Psychedelics Forum panel “Beyond TRD: Non-Hallucinogens and New Indications” on April 27, 2026 from 1:00–2:00 p.m. ET

● FUFU > will return as a sponsor of Bitcoin 2026, taking place April 27–29, 2026 in Las Vegas

● AVX > management will attend New York Fintech Week from April 27–30, 2026, engaging with founders, investors, developers, and fintech leaders across the digital and financial services ecosystem

● VIOT > will present at the dbVIC Deutsche Bank ADR Virtual Investor Conference on April 28, 2026, introducing the company’s ADR program to investors

● AIB > will host a virtual investor webinar on April 28, 2026 at 12:00 p.m. ET to discuss its NYSE listing, commercial progress, infrastructure strategy, and strategic collaborations, followed by Q&A

● EQ > management will present at Oppenheimer’s 2026 Innovation on the Island Event on April 28, 2026 at 7:50 a.m. AST and will be available for investor meetings

● ATHE > will host a virtual KOL event on April 28, 2026 at 1:00 p.m. ET to discuss Multiple System Atrophy, ATH434, Phase 2 data, and Phase 3 planning

● MTEK > will exhibit at Milipol TechX Summit 2026 from April 28–30, 2026 in Singapore, showcasing real-time edge video intelligence technologies at Booth L1-R15

● KLTR > will participate in Forrester B2B Summit North America 2026 from April 26–29, 2026 in Phoenix, showcasing its Agentic Revenue Engagement platform

● PHIO > CEO Robert Bitterman will present during Renmark’s Virtual Non-Deal Roadshow Series on April 29, 2026 at 12:00 p.m. ET, discussing INTASYL, PH-762 clinical progress, and next-stage development priorities

● ZENA > ZenaDrone will present at the Industry 4.0 Deep Tech Showcase on April 29, 2026 in a virtual format, showcasing drone solutions to defense and government stakeholders

● CMRC > management will host an investor briefing at the 2026 Commerce Live leadership conference in Chicago on April 29, 2026 from 12:00–1:30 p.m. CDT

● LTRN > RedChip will host a live webinar on April 30, 2026 featuring the first unrestricted public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform for oncology drug discovery

● AMIX > will present long-term clinical data on transvascular RF ablation for pancreatic cancer pain at ECIO 2026 in Basel, Switzerland, with an oral presentation scheduled April 29, 2026 from 8:30–10:00 a.m. Europe/Zurich

● RZLT > Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism will be presented orally at the Pediatric Endocrine Society Annual Meeting, held April 30–May 3, 2026 in San Francisco, with presentation scheduled May 1 from 8:15–9:15 a.m. PT

● SNAL > will officially launch Survivor Mercs 1.0 on April 30, 2026, marking the game’s transition from Early Access to a full global release. Published under the company’s indie label, Wandering Wizard, Survivor Mercs will be available on Steam, Xbox, and PlayStation. The launch is part of Snail Games’ broader strategy to expand its global games pipeline, support upcoming releases, and diversify its long-term publishing and development portfolio.

● OSTX > will complete its first OST-HER2 regulatory market access filing to the EMA on April 30, 2026, and plans to host a conference call later in April to review new Phase 2b biomarker data and regulatory implications

● ICCM > positive top-line ICESECRET trial data for ProSense® in small renal masses will be presented at ECIO 2026, taking place April 26–30, 2026 in Basel, Switzerland

● OSRH > updated the structure of its VXM01 licensing term sheet with BCM Europe, with up to $815 million in milestones payable directly to OSR Holdings. The April 30, 2026 target date for a definitive agreement remains unchanged

● RYET > announced a pilot project with Columbia University’s Center on Chinese Education and plans to attend the Chinese Language Teachers Association Annual Conference from May 1–3, 2026 in Rhode Island

● FEMY > launched FemaSeed Complete and will showcase its in-office women’s reproductive health portfolio at ACOG 2026 from May 1–3, 2026 in Washington, D.C., at Booth #524

● COCP > will present initial progress from its norovirus challenge study of CDI-988 at ICAR2026, held April 27–May 1, 2026 in Prague

● CLDI > will present RedTail platform and CLD-401 data at the International Oncolytic Virus Conference on April 28, 2026 in Reykjavik, Iceland

● MOB > will exhibit at Modern Day Marine 2026 from April 28–30, 2026 in Washington, D.C., under strategic U.S. partner Noble’s Booth #618, showcasing defense drone technology already deployed in active platforms

● FARM > disclosed litigation-related stockholder demand letters and complaints tied to its Royal Cup merger proxy, while the special meeting remains scheduled for May 1, 2026 at 11:00 a.m. CT in virtual-only format; the company is making voluntary supplemental disclosures to reduce litigation risk delays

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.